Cytek Biosciences, Inc. income statement

In fiscal 2025, Cytek Biosciences, Inc. reported revenue of $201m, up 0.5% on the year before, operating income of −$40.4m (a -20.0% margin) and net income of −$66.5m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Cytek Biosciences, Inc.: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	93	128	164	193	200	201	207
Cost of revenue	41	49	63	84	89	97	97
Gross profit	52	79	101	109	111	104	110
Research and development	14	24	35	44	39	36	37
Selling and marketing	15	25	33	49	49	49	50
General and administrative	9	21	35	44	43	59	68
Operating income	14	9	−2	−28	−21	−40	−45
Interest expense	0	2	3	2	−5	0	0
Income before tax	14	6	1	−16	−6	−30	—
Income tax	−5	3	−1	−4	0	37	40
Net income	19	3	2	−12	−6	−67	−81
Diluted EPS	$0.10	$0.00	$0.02	−$0.09	—	—	−$0.63
Diluted shares (average)	33m	82m	139m	135m	131m	128m	128m
EBITDA	14	10	1	−22	−13	−33	−39

US$ millions unless shown otherwise. Fiscal quarters.

Cytek Biosciences, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	52	57	41	46	52	62	44	48
Cost of revenue	22	24	21	22	25	29	23	20
Gross profit	29	34	20	24	28	33	21	28
Research and development	10	10	10	9	9	9	10	10
Selling and marketing	12	12	13	12	12	13	12	13
General and administrative	11	9	13	14	16	16	18	17
Operating income	−4	3	−15	−11	−9	−6	−18	−11
Interest expense	0	−6	0	0	0	−1	0	0
Income before tax	0	10	−11	−7	−8	−4	—	—
Income tax	−1	1	0	−1	−2	40	1	1
Net income	1	10	−11	−6	−5	−44	−19	−12
EBITDA	−3	5	−13	−10	−8	−4	−17	−10

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CTKB vs MRVI CTKB vs CYRX CTKB vs MLAB

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Cytek Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Cytek Biosciences, Inc.